E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 861.05 USD 0.54% Market Closed
Market Cap: 193.2B USD

Endo International PLC
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Endo International PLC
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
E
Endo International PLC
LSE:0Y5F
Free Cash Flow
$169.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Free Cash Flow
$271.4m
CAGR 3-Years
N/A
CAGR 5-Years
-6%
CAGR 10-Years
-12%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Free Cash Flow
$1.2B
CAGR 3-Years
8%
CAGR 5-Years
22%
CAGR 10-Years
10%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Free Cash Flow
$19.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
G
GH Research PLC
NASDAQ:GHRS
Free Cash Flow
-$42.3m
CAGR 3-Years
-40%
CAGR 5-Years
-171%
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Free Cash Flow
€66.8m
CAGR 3-Years
103%
CAGR 5-Years
N/A
CAGR 10-Years
21%
No Stocks Found

Endo International PLC
Glance View

Market Cap
202.5B USD
Industry
Pharmaceuticals

Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.

0Y5F Intrinsic Value
Not Available

See Also

What is Endo International PLC's Free Cash Flow?
Free Cash Flow
169.5m USD

Based on the financial report for Dec 31, 2022, Endo International PLC's Free Cash Flow amounts to 169.5m USD.

What is Endo International PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
-48%

Over the last year, the Free Cash Flow growth was -48%.

Back to Top